Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next

October 12, 2026
9 min

The Medicine Maker

Objective:

The article examines the objective, findings, and clinical context described in Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith.

Approach:

Current role: Jensen-Smith oversees SOTIO’s preclinical antibody-drug conjugate pipeline for solid tumors, from identifying targets and technologies through preparation for clinical development.
Drug development strategy: She says her team identifies the most critical uncertainty in a program and tests it early, rather than proceeding through questions sequentially.
Career and leadership: She describes moving from laboratory research into leadership as a way to broaden scientific questions, guide teams, and consider how discoveries can be used.

Key Findings:

Jensen-Smith says ADCs combine a tumor-recognizing antibody with potent chemotherapy intended to deliver the chemotherapy to the tumor.
She characterizes biotech as a balance of resources, focus, and freedom, based on her experience across academia, government, pharma, and biotech.
Her advice for scientific teams includes hiring people with different backgrounds and work styles, treating failure as part of science, and listening to team members.

Interpretation:

The interview presents Jensen-Smith’s personal perspective on oncology drug development and scientific leadership, including her emphasis on testing key program uncertainties early.

Limitations:

The supplied article context ends mid-answer during a discussion of challenges in translating discovery science into clinical and commercial realities.
The context provides interviewee perspectives and does not report study data or independently evaluate SOTIO’s pipeline.